RESMED INC (RMD) Stock Analyst Ratings
NYSE:RMD • US7611521078
257.39 USD
+1.13 (+0.44%)
Last: Mar 2, 2026, 03:45 PM
ChartMill assigns a Buy % Consensus number of 74% to RMD. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 303.44. This target is 17.89% above the current price.
- RMD was analyzed by 25 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about RMD.
- In the previous month the buy percentage consensus was at a similar level.
- RMD was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-02 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-30 | Stifel | Maintains | Hold -> Hold |
| 2026-01-30 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-30 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-12-18 | Stifel | Maintains | Hold -> Hold |
| 2025-12-16 | Baird | Downgrade | Outperform -> Neutral |
| 2025-11-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-10-31 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-31 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-21 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-13 | Wells Fargo | Initiate | Equal-Weight |
| 2025-09-18 | Citigroup | Initiate | Buy |
| 2025-08-01 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-08-01 | UBS | Maintains | Buy -> Buy |
| 2025-08-01 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-08-01 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-01 | Stifel | Maintains | Hold -> Hold |
| 2025-08-01 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-07-16 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-07-16 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2025-04-24 | UBS | Maintains | Buy -> Buy |
| 2025-04-24 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-04-24 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-04-24 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-04-24 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-04-21 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-03-05 | Stifel | Maintains | Hold -> Hold |
| 2025-03-05 | Citigroup | Upgrade | Neutral -> Buy |
RESMED INC / RMD FAQ
What is the average price target for RESMED INC (RMD) stock?
25 analysts have analysed RMD and the average price target is 303.44 USD. This implies a price increase of 17.89% is expected in the next year compared to the current price of 257.39.
How do analysts rate RESMED INC (RMD)?
The consensus rating for RESMED INC (RMD) is 74.4 / 100 . This indicates that analysts generally have a positive outlook on the stock.